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DELIVERING CONTRACEPTIVE
VAGINAL RINGS TO
BREASTFEEDING WOMEN
The Progesterone Vaginal Ring (PVR) is a
user-controlled contraceptive that helps
breastfeeding women safely and effectively
space, delay, or limit their next pregnancy.
For the first six months after childbirth, exclusive breastfeeding provides
effective contraception. However, many women do not or are unable to
exclusively breastfeed. Once a woman stops breastfeeding, begins adding
other foods or liquids to her infant’s diet, or starts menstruating, she is at
risk of becoming pregnant and must consider other contraceptive
methods to meet her own family planning goals.
Of the 213 million pregnancies that occurred across the world in 2012, it
is estimated that roughly 40%—about 85 million—were unintended.1
Despite this high unmet need, access to safe, effective, and affordable
family planning methods in low-resource settings is often limited or
nonexistent—especially for postpartum breastfeeding women. For women
seeking to space their births or limit future pregnancies, new methods
that do not require significant health-care resources or infrastructure can
help address the growing demand.
The Population Council and partners developed the PVR to help address
the unmet need for contraception among breastfeeding women. The ring
provides a convenient option that adds choices for new mothers and
promotes optimal infant nutrition and health.

HOW THE PVR WORKS
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The PVR releases a continuous low dose of the natural hormone
progesterone, which reinforces the inhibitory effect of breastfeeding on
ovulation and delays the return of the menstrual cycle, therefore
preventing pregnancy. A woman can begin using the ring as early as four
weeks after birth if her menstrual cycle has not returned. A single ring can
be used for three months and can be replaced with a new ring up until
the child’s first birthday.
In clinical trials, the PVR was 98.5% effective in preventing pregnancy
when used continuously by women who breastfeed at least four times a
day, which motivates women to breastfeed regularly. The PVR is safe for
both mothers and babies, with few side effects—some women reported
cramping, weight gain, breast tenderness, and spotting. Most women
report a high degree of satisfaction and acceptance using the ring. Also,
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ADVANCING NUTRITION
AND INFANT HEALTH WITH
THE PVR: FAST FACTS
Breastfeeding can lead to
improved health and
nutrition for newborns—
and optimal breastfeeding
saves lives.
As the PVR does not affect
quality or amount of breast
milk, it may be an attractive
option for postpartum
women who want a method
that is minimally invasive,
convenient, and discreet,
without worrying about any
potential impact on their
health or the health of their
infant.

ongoing research suggests women may experience other
benefits from breastfeeding, such as reduced risk of
ovarian and breast cancer.2-3

all ages) and SDG 5 (achieving gender equality and
empowerment of all women and girls).13
And, with sustained investment in planning the introduction
of a new method, health sectors play a major role in
ensuring women can access a range of products that best
meet their needs, when and where they need them. To help
make this a reality, product developers and partners often
employ what’s called a “Total Market Approach.” This
approach brings together the public and private sectors (e.g.,
social marketing groups, NGOs, and commercial
organizations). Through a highly coordinated effort, partners
are able to leverage resources and knowledge to reduce
burden on the public sector, increase health-care-system
capacity, and ensure access.

Unlike other contraceptives suitable for breastfeeding
women such as the IUD, the PVR is entirely under a
woman’s control—offering discreet protection from
pregnancy, and giving the woman control to insert and
remove the ring conveniently on her own. This reduces the
need for involvement by skilled health-care providers, who
often are in short supply in underserved settings, including
rural areas where timely, convenient access to quality
health-care may be scarce.

ADDING VALUE TO THE METHOD MIX

The Population Council supports the Total Market Approach
and is invested in generating the evidence needed to
facilitate introduction of the PVR in sub-Saharan Africa and
India. Researchers have been: assessing interest in and
support for the PVR among decision-makers who determine
which products are made available in their countries;
determining acceptability of the ring among breastfeeding
women, partners, providers; and streamlining pathways for
introduction. With the addition of the PVR to the World
Health Organization’s Essential Medicines List, local
regulatory authorities now have more evidence supporting
the value of introducing the PVR within their family planning
programs.

Traditionally, the lactational amenorrhea method (LAM)
has been recognized as an effective way to delay return to
fertility in breastfeeding women by delaying a woman’s
next menstrual cycle.4-10 However, research suggests very
low numbers of breastfeeding women (less than 5%) report
compliance with LAM criteria.11
User-controlled methods such as vaginal rings represent
an important advancement in family planning. The PVR is
unique because it offers an accessible, easy-to-use method
without requiring frequent trips to the pharmacy or ondemand access to a trained health-care provider. Similarly,
rural communities need access to products that do not
require sophisticated methods of storage to ensure the
product remains safe, effective, and accessible. The PVR
does not require special preparation or refrigeration.
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PROMOTING INFANT SURVIVAL
Nearly 7 million children under the age of 5 die each year,
mostly due to preventable causes. And newborn deaths
represent nearly half of all deaths in children under age 5.
However, breastfed children have at least a six times
greater chance of survival in the first months of life than
nonbreastfed children, and the health benefits of
breastfeeding are particularly critical in developing
countries.12 The PVR not only provides contraceptive
efficacy for new mothers, but also offers a method whereby
the efficacy relies on optimal breastfeeding practices,
holistically contributing to better outcomes for infants.
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